Slide 1: Agilent Technologies Q4 FY2024 Financial Results Overview
Agilent Technologies Q4 FY2024 Financial Results Overview
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company’s revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and relat
Slide 3: Agilent Q4 2024 Results
Agilent Q4 2024 Results Revenue Operating Margin EPS $1.70B 27.4% (2) $1.46 (2) +0.8% reported -40 basis points y/y +6% y/y -0.3% core(1)(2) +0.5% FX, +0.6% M&A Capital Allocation $481M operating cash flow | $859M towards M&A | $93M invested in capex $335M to purchase 2.4M shares | $68M in dividends
Slide 4: Agilent FY24 Results
Agilent FY24 Results Revenue Operating Margin EPS $6.51B 26.4% (2) $5.29 (2) -4.7% reported -3% y/y -100 basis points y/y -4.7% core(1)(2) -0.1% FX, +0.1% M&A Capital Allocation $1.8B operating cash flow | $0.9B in M&A | $0.4B invested in capex $1.2B to purchase 8.4M shares | $0.3B in dividends Insi
Slide 5: Q4 Revenue by Geography, Product Type and Segment
Q4 Revenue by Geography, Product Type and Segment Geography Product Type Segment Americas Europe Consumables Instruments LSAG ACG Services Informatics 27% 25% 40% 36% 49% 64% 26% 33% DGG Asia Pacific 11/25/2024 5 Q4'24 Financial Results Overview
Slide 6: FY24 Revenue by Geography, Product Type and Segment
FY24 Revenue by Geography, Product Type and Segment Geography Product Type Segment Americas Europe Consumables Instruments LSAG ACG Services Informatics 27% 25% 40% 36% 50% 64% 25% 33% DGG Asia Pacific 11/25/2024 6 Q4'24 Financial Results Overview
Slide 7: Q4 Revenue by End Market
Q4 Revenue by End Market Q4 Core Growth(1) Results by End Market Chemicals & Academic & Diagnostics & Environmental & Pharma Advanced Food Government Clinical Forensics Materials -1% -1% +7% +1% -3% -6% Improving market for Results improve Strong high-single Solid growth in Asia- Commercial labs Slo
Slide 8: Q4 & FY24 Results by Segment
Q4 & FY24 Results by Segment Life Sciences and Applied Markets Group Revenue Growth Operating Margin Insights Q424 $833M -1% Reported 28.0%(3) Q4 revenue was in-line with expectations as instrument growth rates continue to see -1% Core (1)(2) -60 bps y/y steady improvement. LSAG results continue to
Slide 9: Our New Market-focused Organizational Structure
Our New Market-focused Organizational Structure Life Sciences and Agilent CrossLab Applied Markets Group Diagnostics Markets Group (ACG) (AMG) Group (LDG) FY24 Revenue FY24 Revenue FY24 Revenue ~$2.5B ~$2.7B ~$1.3B Product Platforms Product Platforms Product Platforms LC Analytical Lab Consumables G
Slide 10: Guidance and Forward-looking Considerations
Guidance and Forward-looking Considerations Based on forecasted currency exchange rates Q1 25 Guidance (1) Low End High End FY 25 Guidance (1) Low End High End Net Revenue ($M) $1,650 $1,680 Net Revenue ($M) $6,790 $6,870 Core Revenue Growth (2) -2.0% -0.2% Core Revenue Growth (2) +2.5% +3.5% -0.3%
Slide 11: Q4'24 Financial Results Overview
11/25/2024 11 Q4'24 Financial Results Overview